| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| Apellis Rare Blood Disease Drug Tops Alexion’s in Head-to-Head Test | Frank Vinluan | 01/07/20 | Boston |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval | Frank Vinluan | 11/08/19 | New York |
| Disc Medicine Launches With $50M to Advance New Anemia Treatments | Sarah de Crescenzo | 10/29/19 | Boston |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| Celgene Files for FDA Approval of Blood Disease Drug | Frank Vinluan | 04/05/19 | New York |
| Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More | Alex Lash | 12/21/18 | National |
| With New Results, FibroGen’s Anemia Pill Inches Closer to FDA Review | Ben Fidler | 12/20/18 | San Francisco |
| Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder | Frank Vinluan | 07/09/18 | Boston |
| Akebia Merges With Keryx as Anemia Drug Race Nears Finish Line | Ben Fidler | 06/28/18 | Boston |
| For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs | Alex Lash | 06/15/18 | San Francisco |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins | Ben Fidler | 02/03/17 | National |
| FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits | Ben Fidler | 01/30/17 | San Francisco |
| Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push | Ben Fidler | 12/20/16 | Boston |
| Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More | Alex Lash | 12/16/16 | National |
| Bay Area Researchers Take A CRISPR Cut At Sickle Cell Disease | Alex Lash | 10/12/16 | San Francisco |
| Roundup: Owlchemy, TheWaveVR, Fe3 Medical, & Rackspace Buyout? | Angela Shah | 08/09/16 | Texas |
| Texas Government Adds $3.5M to Fe3 Series B for Anemia Treatment | David Holley | 08/08/16 | Texas |
| After Rival Stumbles, Relypsa Gets $1.5B Buyout Bid From Galenica | Ben Fidler | 07/21/16 | San Francisco |
| Anemia Ups and Downs: Agios Hit On One Drug, Touts Data For Another | Ben Fidler | 06/11/16 | Boston |
| East Coast Biotech Roundup: Celldex, Ensemble, CRISPR Battle & More | Ben Fidler | 03/10/16 | Boston |
| InCube Labs Startup Fe3 Plans Iron-Delivering Patch For Anemia | David Holley | 03/04/16 | Texas |
| With New Data, Highs and Lows For Akebia, Flexion, Tetraphase | Ben Fidler | 09/08/15 | Boston |
| Global Blood Thera Nabs $120M IPO, Doubles Share Price On First Day | Alex Lash | 08/11/15 | San Francisco |
| Amag Seeks New Chapter With $700M Cord Blood Registry Purchase | David Holley | 06/30/15 | Boston |
